Challenges Mapping Oncology Billing and Claims Data into the OMOP CDM

I’ve been reviewing discussions here around claims modeling, provider attribution, and oncology-related ETL challenges in OMOP, and I wanted to get community insight into handling oncology billing workflows within the CDM. Recent industry discussions also highlight how specialized oncology billing has become due to infusion complexity, prior auth requirements, and reimbursement variance across payers.

In oncology practices, common billing challenges include:

  • Separate professional and facility claims for infusion services
  • High prior authorization dependency for chemotherapy and biologics
  • Buy-and-bill reimbursement workflows
  • Denials related to medical necessity, sequencing, or infusion timing
  • Multiple provider roles tied to a single claim line.

I recently came across this overview on common challenges oncology practices face with specialized billing workflows.

It raised a few technical questions for OMOP implementation:

  1. How are teams representing oncology billing events while preserving links between infusion encounters, drug exposure, and financial claims?
  2. Are authorization and denial metadata typically stored outside OMOP, or modeled through extensions?
  3. For chemotherapy administration and infusion billing logic, what has worked best for operational analytics?
  4. Has anyone successfully linked registry-level oncology data with claims-level billing provenance without losing workflow fidelity?

I’d also be interested in how teams working with oncology-focused revenue cycle data approach vendor benchmarking or workflow optimization.

Would really appreciate hearing how others are approaching these oncology billing challenges, especially for infusion-heavy or payer analytics environments.

Sources that I have visited, but not sure which way to go in terms of getting the right help. Looking to connect with an expert.

I have visited this Oncology billing source for oncology billing practices. Are they professional enough to consult?

Data Standardization – OHDSI

Hi @Usamakhan001:

Welcome to the family.

In general, the OMOP CDM is a patient-centric model, not a claim or institution-centric model. So, things matter that happen to the patient. As far as billing is concerned, you have the COST table to attach a reimbursement claim to the events. In particular:

  1. The infusion encounters are in the PROCEDURE table, and the cost for the infusion service should be linked to these records. If the drug gets claimed, same thing, the COST table record needs to get linked to the DRUG_EXPOSURE record as described there.
  2. It’s not part of OMOP. I don’t know about any Extension, but it could well be. If not feel free to submit your solution as an Extension.
  3. Currently, chemotherapy is analyzed for its effects (survival, toxicity). Health economics would be an important new use case.
  4. Institutions routinely aggregate EHR, registry and claims data, because only together they have the breadth and depth for cancer research.

Please come to the Oncology WG, oncology RWE issues are being discussed all the time.